|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||4.6900 - 5.0000|
|52 Week Range||0.3000 - 6.7900|
|Beta (5Y Monthly)||-1.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2020 - Aug 17, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Humanigen, Inc. (HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, today announced the appointment of Bob Atwill, MBA, to the newly created role of Head of Asia-Pacific, effective immediately. Mr. Atwill will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, and will initially serve on a consultancy basis.
Humanigen, Inc., (HGEN) ("Humanigen"), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and business update at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11th, 2020 at 2:00 pm Eastern Time. The conference is being held in a virtual format.
Conference call and webcast scheduled for today, August 3, 2020 at 4:30 pm EDTBURLINGAME, CA / ACCESSWIRE / August 3, 2020 / Humanigen, Inc.